PROVEN EFFECTIVENESS OF HBOT IN TREATING COVID-19

 

Clinical trials categorically show that HBOT (hyperbaric oxygen therapy) stops viral progression and COVID-19 pneumonia, rejuvenates hypoxic organs, and speeds up the body's natural healing process.
The unsurpassed success of HBOT remains, by and large, unpublished. In the emergency context of COVID-19, the pharmaceutical industry is licensed to test numerous drugs without formal experimentation, despite an increase in harmful side effects and deaths, in the race to patent a lucrative drug cure.
In contrast, hyperbaric oxygen therapy is a well-established, drug-free, and non-invasive treatment. It has been officially recognized and classified by the World Health Organization as a treatment for COVID, and is approved by the FDA for a number of respiratory disorders and tissue ailments associated with COVID-19.

 

 

 

 

During the current pandemic, several hospitals from China to the United States have been using hyperbaric oxygen therapy (HBOT) to treat dozens of seriously ill COVID-19 patients with pneumonia and severe respiratory distress, in addition to multiple high-risk factors ( for COVID mortality), such as obesity, diabetes, heart disease and hypertension. The result? After a short cycle of HBOT, patients have consistently made a quick and full recovery.
Referring to the historic success of HBOT for lung diseases and viruses, the United States National Institute of Medicine and Health cites: "The concept of using respiratory gases at ambient pressures in the treatment of disease dates back three centuries. In 1662 the Hyperbaric air was used by Henshaw (UK) for the treatment of lung afflictions.
In 1834, Junod (France), treated a wide variety of ailments, including cardiovascular and pulmonary diseases, carcinomas and diabetic feet at pressures between 2 and 4 absolute atmospheres. In the early 1900s, Orval J Cunningham (USA) observed that people with heart disease and other circulatory disorders became ill at altitude and improved at sea level forming the basis for their use of hyperbaric air. From 1918 to 1930, he successfully and consistently treated patients with the Spanish flu epidemic with hyperbaric air. "Over the past decades, HBOT has proven effective in treating new viruses, including the SARS virus ( CoV1) in 2002-2003.
Around the world, dozens of hospitals are treating COVID-19 patients with hyperbaric oxygen therapy.

 

 

 ARE THERE TECHNICAL DIFFICULTIES IN CARRYING OUT THE EXPERIMENTATION?

 

Basically no. The test requires the availability of a chamber and hyperbaric technicians, as well as the use of a limited number of appropriate medical personnel supported by your existing hospital facility. There is also a wide availability of positive patients at this time.
For the time being, it would suffice to start national trials of HBOT, over a period of only a few days, with asymptomatic or mildly symptomatic patients to provide important data. The trials will evolve towards symptomatic patients and those with pre-existing conditions, taking into account the precautions of the case. In the emergency context of COVID-19, numerous drugs have been tested without formal experimentation, and despite the risks of side effects in patients.

 

THE BEST SOLUTION TO FIGHT A PANDEMIC

 

 EFFICIENCY EVEN DURING THE INITIAL STAGES

HBOT (hyperbaric oxygen therapy) combats the progression of the virus, preventing the decrease in the patient's conditions and the need for hospitalization or intensive care (ICU). The results are especially effective when treatment begins on time. No other solution has achieved the consistently high results of HBOT.

 

POTENTIAL FOR GROUP THERAPIES

 

Hyperbaric oxygen chambers now follow current World Health Organization guidelines for HBOT / COVID-19 disinfection and operation of single and multi-color chambers, and in doing so are well positioned for collective use. Large numbers of patients can now be treated and cured in a short period of time, stopping the progression of symptoms and the spread of infection to others.
The 24-seater AC19 DRASS chamber is specifically designed for the safe treatment of COVID-19. Patients are separated from each other by transparent seat-to-ceiling protective partitions, which can be easily removed to make way for patients on stretchers. Respiratory gases are delivered individually through oronasal masks. The 2nd stage regulators grant the supply on demand, while the exhaled gas is discharged from the chamber through a special line and disinfected

 

 LESS FINANCIAL AND PHYSICAL PRESSURE IN ICU AND HEALTH CENTERS

 

Hyperbaric oxygen therapy relieves stress on the healthcare system and decreases the number of highly specialized nurses and doctors required by dramatically reducing the number of hospitalized patients, and the number that eventually require admission to the ICU (intensive care units)

 

Oxygen is the life force of the body and therefore it is not surprising that it has been shown to be more effective, and cost effective, in the treatment of viruses, respiratory disorders, tissue and organ damage.
An HBOT camera is infinitely less costly compared to setting up and managing intensive care units with their expensive medical equipment and expensive medications.

 

 HERD IMMUNITY

 

Upon completion of a comprehensive verification of the efficacy of HBOT, for individuals without contraindications, the hyperbaric chamber greatly reduces the danger and complications of COVID-19, allowing the resumption of normal activities and a reassessment / acceleration of containment measures in force

 

 STRUCTURAL SOLUTION

 

DRASS has already completed the AC-19 project for the rapid and industrial construction of high-capacity and customized transportable chambers for the treatment of COVID-19 positive patients. Recovery rates are unmatched by any treatment (drug or non-drug) so far tested by the pharmaceutical industry.

 

INVALUABLE AGAINST COVID-19

 

WHAT IS THE PRINCIPLE BEHIND THE USE OF HBOT?

If the virus was a master key and the locks are our cells, hyperbaric oxygen alters both the key and the lock so that the virus cannot access and do damage.

HBOT (Hyperbaric Oxygen Therapy) increases nitric oxide, a gas molecule that alters the lipid (fat) structure of the virus and modifies the viral RNA. Doing so blocks replication of the virus and prevents it from attaching to the ACE2 receptor. These promising results have been seen in the treatment and viral suppression of HIV AIDS, and in the recovery of patients with SARS-CoV-1 during the SARS epidemic of 2002-2003.

 

 ¿HOW DOES HBOT REDUCE LUNG DAMAGE?

 

By allowing the diffusion of a higher concentration of oxygen to hypoxic (oxygen starved) organs, HBOT successfully treats lung trauma and pneumonia. Reduces and destroys cytokines and interleukin 6 molecules that fuel the inflammation responsible for respiratory failure. Hemoglobin blood cells are completely filled with oxygen molecules (4 molecules can bind to each blood cell). This accelerated oxygenation effectively transports vital repair materials, such as fibronectin and proteoglycan, to reach areas of damage and accelerate the restoration process

 ¿WHY DOES HBOT WORK COVID-19?

 

In healthy people, the virus is normally killed by nitrogen monoxide and oxygen free radicals.
More than 50% of the mortality in COVID-19 patients (not treated with HBOT) has occurred in patients with pre-existing dysmetabolic hypercholesterolemia, diabetes, obesity and / or cardiovascular diseases related to the deterioration of normal endothelial function and reduced production of nitrogen monoxide.

In patients with comorbidities, hyperbaric oxygen therapy restores normal nitrogen monoxide synthesis (through the gene expression of nitric oxide synthase) allowing the body to eliminate the virus as it does in a healthy person. This genetic activation (up-regulation) is reinforced by the implementation of a cycle of HBOT sessions.
All patients with high-risk comorbidities who started HBOT before or in the early stages of hospitalization have made a full recovery.

 ¿HOW MANY HYPERBARIC SESSIONS ARE RECOMMENDED?

 

The specified pressure and duration protocol includes five hyperbaric treatments, one per day for 5 consecutive days. Each session is approximately 60 minutes

 

 HOW SUCCESSFUL IS HBOT AGAINST COVID-19?

 

In clinical trials to date, all critically ill COVID-19 patients in intensive care who were treated with hyperbaric oxygen therapy have made a full recovery. However, early treatment is always advisable for an effective recovery that prevents viral progression that requires intensive care.
The results, of course, are highly dependent on the severity of any pre-existing conditions (comorbidities) that are known to be high-risk factors in relation to COVID-19. That said, of the dozens of critically ill patients who have accessed a cycle of HBOT, most also had multiple pre-existing high-risk factors (for COVID complications) such as diabetes, heart disease, and obesity, and yet all were recovered.

 

 suscipit.